Search Bar & Filters
Found 79 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating GNT0004, a gene therapy using a recombinant adeno-associated viral vector designed to deliver a shortened but functional dystrophin gene to treat Duchenne muscular dystrophy DMD in boys. DMD is caused by mutations in the dystrophin gene, leading to muscle damage from lack of this key protein. This therapy aims to slow disease progression by producing dystrophin in heart and skeletal muscles. The study has three parts. Part 1 involved testing two doses of GNT0004 in five boys to determine the best dose with acceptable safety. Part 2 is a randomized, blinded phase lasting 18 months where participants receive either GNT0004 or a placebo after 18 months, those on placebo switch to GNT0004 and vice versa. Part 3 is a long-term follow-up lasting up to five years to monitor safety and treatment effects in all participants who received GNT0004. Participants undergo assessments including muscle biopsies, blood tests, MRI scans, and functional tests like the North Star Ambulatory Assessment, performed at various times throughout the study. Researchers monitor safety by tracking adverse events and immune responses. Long-term follow-up includes measuring muscle function and respiratory capacity over five years. The study involves ambulant boys aged 6 to 10 years with confirmed DMD who meet specific health criteria.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of the drug S230815 in children aged 2 to 12 years with Developmental Epileptic Encephalopathy caused by a specific genetic variant in the KCNT1 gene. This first-in-human, open-label study includes pediatric participants with genetically confirmed disease and aims to understand how the drug behaves in the body and its effects on seizure frequency. The study consists of a screening period followed by two parts Part 1 involves testing multiple ascending doses of S230815 to find appropriate dosing levels. Part 2 is a long-term treatment extension where participants who finish Part 1 continue receiving S230815 for up to 72 weeks, staying in the same dosing group assigned initially. The drug is given as a solution for injection. Participants will be closely monitored throughout the study with assessments including recording seizures through daily logs and video electroencephalogram vEEG, blood and cerebrospinal fluid tests to study drug levels, and safety evaluations for adverse events. The total study duration can be up to 116 weeks, including long-term follow-up to observe effects and safety. Researchers also track use of rescue medications and other clinical measures related to epilepsy.
Actively Recruiting
This research aims to evaluate the long-term effectiveness of mirikizumab in children and adolescents aged 2 to 19 years with moderate-to-severe ulcerative colitis or Crohns disease. The study is a phase 3, open-label, multicenter trial focusing on the treatment of these inflammatory bowel diseases and is sponsored by Eli Lilly and Company. It addresses the need for ongoing management of these chronic conditions in pediatric populations. Participants receive mirikizumab by subcutaneous injection in doses tailored to their weight across multiple administrations. In cases where response is lost, intravenous rescue dosing is available. This long-term extension study may include up to 44 visits over about 172 weeks. Additional treatment could be accessible through a Continued Access Period after the main study. During the study, participants are closely monitored through clinical assessments including remission and response evaluations using established scores like the Modified Mayo Score for ulcerative colitis and the Pediatric Crohns Disease Activity Index for Crohns disease. Researchers also examine endoscopic and histologic remission, corticosteroid use, and inflammation markers such as C-reactive protein. Safety and efficacy are tracked throughout, with participants undergoing regular visits for evaluations and treatment administration for nearly three and a half years.
Actively Recruiting
Researchers are conducting a master protocol trial designed to efficiently study several different drugs for children and young adults with various types of cancer. This approach allows multiple clinical trials under one common research plan, with each trial focusing on specific cancers like desmoplastic small round cell tumor, synovial sarcoma, and Ewings sarcoma. New drug studies may be added over time as new treatments emerge. Participation depends on how long the treatment benefits last. The study evaluates combinations of drugs given in cycles, including intravenous and oral medicines such as ramucirumab, cyclophosphamide, vinorelbine, gemcitabine, docetaxel, abemaciclib, irinotecan, and temozolomide. Different treatment groups receive specific drug combinations tailored to the cancer type, with treatment cycles lasting 21 or 28 days depending on the regimen. Each group is randomized to receive either an experimental drug combination or an active comparator without any blinding. Participants will be involved from screening through treatment and monitored regularly. Researchers will assess how many participants are assigned to each specific intervention plan within the first four weeks and track treatment effects. Participants must have measurable or evaluable disease, adequate organ function, and meet performance status criteria. Female participants of childbearing potential undergo pregnancy testing and must use contraception during and after treatment. Safety, adherence, and side effects are carefully monitored throughout the study, which is expected to continue until 2027.
Actively Recruiting
This research aims to better understand Congenital Myasthenic Syndromes CMS caused by mutations in the genes DOK7, MUSK, AGRN, or LRP4. It focuses on evaluating disease activity by collecting clinical assessments to study symptoms and quality of life in affected participants. The study is observational and seeks to gather detailed information about the natural history of CMS over time. Participants will attend up to four study visits where clinical assessments will be performed. These visits will collect data on participants symptoms and health status related to CMS, including scores like the Quantitative Myasthenia Gravis QMG and other quality of life measures. The study does not involve treatment but focuses on monitoring and documenting disease progression and healthcare utilization. During the study, researchers will collect and review data such as diagnosis details, medication use, healthcare visits, and changes in health status over a period of up to 12 months. Participants will undergo assessments including clinical evaluations and questionnaires to measure fatigue, daily activities, and general health. This information will help to provide summary statistics about CMS and support understanding of this conditions impact on patients.
Actively Recruiting
Researchers are evaluating CRD-4730, an oral drug, in a Phase 2 clinical trial involving adults with Catecholaminergic Polymorphic Ventricular Tachycardia CPVT. This study aims to assess the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of CRD-4730. Participants will be part of a randomized, double-blind, placebo-controlled crossover study to better understand how CRD-4730 affects CPVT symptoms and treatment responses. Participants will be randomly assigned to one of three sequences in a 3-period crossover design. Each participant will receive two different doses of CRD-4730 and one matching placebo dose in a random order. The study includes multiple dosing periods where participants take tablets of CRD-4730 or placebo, allowing researchers to compare the effects and tolerability of different doses against placebo. During the trial, participants will undergo various assessments to monitor safety, drug levels, and effects on their condition from baseline to Day 101. The study involves close monitoring of heart function and other health measures, with outcome evaluations occurring at multiple timepoints. This will help researchers understand how the drug behaves in the body and its impact on CPVT symptoms, with the trial lasting several months to complete all study periods and follow-ups.
Actively Recruiting
Researchers are evaluating MAS825 arumakimig in a phase II trial to study its clinical efficacy, safety, and tolerability in both pediatric and adult participants with Stills disease. This trial includes individuals who have had an inadequate response to IL-1, IL-6, or other available therapies. Participants with associated lung disease or macrophage activation syndrome may also join the study, which lasts approximately 16 months across multiple centers. Participants receive MAS825 in an open-label, single-arm design with no placebo group. The study consists of three periods Screening, Treatment Period 1, and Treatment Period 2. The treatment aims to assess response based on clinical criteria and biomarker levels. The drug is administered under medical supervision, and participants are monitored throughout the trial. During the study, participants undergo various assessments including clinical response evaluations on Day 85, biomarker measurements, physician assessments, and quality of life questionnaires. The study also tracks changes in glucocorticoid dose and disease activity over up to 15 months. Safety and tolerability are closely monitored, and the total participation time spans about 16 months from screening through treatment and follow-up.
Actively Recruiting
Researchers are evaluating the drug sarilumab in children and adolescents aged 1 to 17 years with Systemic Juvenile Idiopathic Arthritis sJIA. The study aims to describe how sarilumab behaves in the body pharmacokinetics, its effects pharmacodynamics, efficacy, and long-term safety in this population to determine an appropriate dose and treatment regimen. This is a Phase 2 open-label trial sponsored by Sanofi. Participants will receive one of two ascending doses or an additional intermediate dose of sarilumab by subcutaneous injection based on body weight. The selected dose will be administered once identified. Treatment begins with a 12-week core phase followed by a 144-week extension phase during which sarilumab continues to be given. After treatment, there is a 6-week post-treatment follow-up. Throughout the 166-week total study duration, participants will be monitored with various assessments including blood tests to measure drug levels and disease activity, evaluations of adverse events, and questionnaires to assess well-being and symptoms. Measurements like juvenile arthritis response rates and disease activity scores are tracked during both the core and extension phases. Safety, including injection site reactions and changes in glucocorticoid use, is also followed closely.
Actively Recruiting
Researchers are evaluating how well CagriSema and cagrilintide help children and adolescents aged 8 to under 18 years with excess body weight lose weight. This phase 3 study compares these new study drugs with semaglutide, a medication already prescribed for adolescents and adults, and a placebo. The trial aims to understand the efficacy, safety, and pharmacokinetics of these treatments for weight management in young people with overweight or obesity. Participants are randomly assigned to receive once weekly subcutaneous doses of either CagriSema a combination of cagrilintide and semaglutide, cagrilintide alone, semaglutide alone, or placebo in a dose escalation regimen for up to 16 weeks, followed by maintenance for a total of 52 weeks in the main study. Those who participate in the extension study will continue receiving either CagriSema or cagrilintide for up to an additional 156 weeks. Participants receiving semaglutide do not enter the extension phase. The placebo group will receive a matched placebo during the main phase and then continue on the CagriSema regimen during the extension. During the study, participants will be closely monitored through various assessments including body mass index BMI changes, body weight, fat and muscle measurements by imaging methods like MRI and DXA scans, blood tests for metabolic markers, and quality of life questionnaires. These evaluations occur at baseline, week 68, and for some measures, week 224. Safety is monitored by tracking adverse events and other health indicators. The total participation time is about 1.5 years in the main study and up to nearly 5 years if including the extension phase.
Actively Recruiting
This research aims to describe the characteristics, clinical outcomes, and event rates in participants with propionic acidemia PA, a rare metabolic disorder. It is a non-interventional, observational, global, multicenter study that collects data retrospectively from medical records to better understand PA over time. Data will be gathered by reviewing medical records from various study sites, including hospitals, clinics, and academic centers. Participants included will be those diagnosed with PA confirmed by genetic testing, with records documenting specific metabolic events. The study will cover up to 10 years of medical history and events. Participants involvement consists of allowing researchers to review their medical records to collect information about metabolic decompensation events, hospitalizations, and urgent healthcare visits related to PA. Researchers will analyze the number and severity of these events, along with hospitalization data, to understand PAs clinical impact. The study does not involve direct treatment or interventions and focuses on data collection and analysis.
1-10 of 79
1